
NYSEHealthcareMedical - Devices
最新資料
US$85.21
+US$0.97 · +1.15%
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
前收盤價
US$85.21
+US$0.97 · +1.15%
盤中時間採用ET。市場資料可能有所延遲。
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
日內區間
目前US$85.21
52週區間
目前US$85.21
盤中時間採用ET。市場資料可能有所延遲。
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
日內區間
目前US$85.21
52週區間
目前US$85.21
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 60.68億 USD | 54.4億 USD | 50.1億 USD | 53.82億 USD | 52.33億 USD |
| 銷貨成本 | 13.27億 USD | 11.18億 USD | 10.37億 USD | 11.67億 USD | 12.26億 USD |
| 毛利 | 47.41億 USD | 43.22億 USD | 39.73億 USD | 42.15億 USD | 40.07億 USD |
| 研究與開發 | 10.79億 USD | 10.53億 USD | 9.63億 USD | 9.45億 USD | 9.03億 USD |
| 銷售、一般及管理費用 | 20.85億 USD | 17.89億 USD | 15.83億 USD | 15.68億 USD | 14.93億 USD |
| 營業費用 | 31.05億 USD | 29.43億 USD | 25.45億 USD | 25.13億 USD | 23.96億 USD |
| 利息收入 | 1.48億 USD | 1.2億 USD | 6720萬 USD | 3550萬 USD | 1740萬 USD |
| 利息支出 | — | 1980萬 USD | 1760萬 USD | 2620萬 USD | 2480萬 USD |
| 折舊和攤銷 | 1.57億 USD | 1.55億 USD | 1.45億 USD | 1.4億 USD | 1.35億 USD |
| 營業利益 | 16.36億 USD | 13.79億 USD | 14.27億 USD | 17.02億 USD | 16.1億 USD |
| 淨利 | 10.74億 USD | 41.75億 USD | 14.02億 USD | 15.22億 USD | 15.03億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$101.7
上漲空間 19.35%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2020年6月1日 | 3:1 | — | — |
股票分割 | 2015年12月14日 | 2:1 | — | — |
股票分割 | 2010年5月28日 | 2:1 | — | — |
已生效 2020年6月1日
3:1
已生效 2015年12月14日
2:1
已生效 2010年5月28日
2:1
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T940.09億0.07%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI16.61億0.07%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO13.88億0.08%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO11.3億0.50%2264億 USD0.03%US$81.14+0.92%
iShares Core S&P 500 ETFIVV6.46億0.07%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY5.94億0.07%8172億 USD0.09%US$778.57+0.60%
Vanguard Morningstar Value ETFVTV4.99億0.19%2624億 USD0.03%US$220.59+0.44%
Vanguard Morningstar Mid-Cap Growth ETFVOT4.01億1.17%341億 USD0.05%US$302.48+1.55%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
Vanguard Morningstar Mid-Cap Growth ETFVOTAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。